Safe Harbor Fiduciary LLC Has $1.36 Million Stake in Eli Lilly and Company (NYSE:LLY)

Safe Harbor Fiduciary LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,758 shares of the company’s stock after purchasing an additional 20 shares during the period. Eli Lilly and Company accounts for about 1.4% of Safe Harbor Fiduciary LLC’s investment portfolio, making the stock its 20th biggest holding. Safe Harbor Fiduciary LLC’s holdings in Eli Lilly and Company were worth $1,357,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Safeguard Investment Advisory Group LLC lifted its position in shares of Eli Lilly and Company by 7.3% in the fourth quarter. Safeguard Investment Advisory Group LLC now owns 2,426 shares of the company’s stock valued at $1,873,000 after buying an additional 165 shares during the last quarter. Scissortail Wealth Management LLC increased its holdings in shares of Eli Lilly and Company by 11,660.0% during the fourth quarter. Scissortail Wealth Management LLC now owns 588 shares of the company’s stock worth $454,000 after purchasing an additional 583 shares during the period. Sentinus LLC lifted its position in shares of Eli Lilly and Company by 10.6% during the 4th quarter. Sentinus LLC now owns 574 shares of the company’s stock valued at $443,000 after acquiring an additional 55 shares during the period. SGL Investment Advisors Inc. lifted its position in Eli Lilly and Company by 12.1% during the fourth quarter. SGL Investment Advisors Inc. now owns 305 shares of the company’s stock worth $235,000 after purchasing an additional 33 shares during the period. Finally, Sherbrooke Park Advisers LLC lifted its position in Eli Lilly and Company by 15.2% during the fourth quarter. Sherbrooke Park Advisers LLC now owns 1,227 shares of the company’s stock worth $947,000 after purchasing an additional 162 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on LLY. Hsbc Global Res cut shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price objective for the company. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research report on Friday, January 17th. Guggenheim reissued a “buy” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Citigroup decreased their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,011.37.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 3.3%

NYSE LLY opened at $757.23 on Friday. The business’s 50-day moving average price is $797.84 and its two-hundred day moving average price is $806.14. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The firm has a market capitalization of $717.65 billion, a PE ratio of 64.67, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business’s revenue was up 45.2% compared to the same quarter last year. During the same period last year, the company posted $2.58 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.79%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.